ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4- T Cells

Liu, Qiao*; Wang, Lisha; Lin, Huayu; Wang, Zhiming; Wu, Jialin; Guo, Junyi; Wen, Shuqiong; Ran, Ling; Yue, Zhengliang; Su, Xingxing; Wu, Qing; Tang, Jianfang; Li, Zhirong; Hu, Li; Xu, Lifan; Ye, Lilin*; Huang, Qizhao*南方医科大学; 中山大学
Frontiers in Immunology2022-6-16DOI: 10.3389/fimmu.2022.875718
6被引12阅读
引用收藏
分享

摘要

Cytotoxic CD8(+) T cells are the main focus of efforts to understand anti-tumor immunity and immunotherapy. The adoptive transfer of tumor-reactive cytotoxic CD8(+) T lymphocytes expanded and differentiated in vitro has long been considered the primary strategy in adaptive anti-tumor immunity, however, the majority of the transferred tumor antigen-specific CD8(+) T cells differentiated into CD39(+)CD69(+) exhausted progenies, limiting its effects in repressing tumor growth. Contrarily, less attention has been addressed to the role of CD4(+) T cells during tumorigenesis. Using a mouse model of metastatic melanoma, we found that transferring tumor-specific CD4(+) T cells into recipients induces substantial regression of the established metastatic tumors. Notably, in vitro activated CD4(+) T cells developed into cytotoxic CD4(-) T cells in vivo and get exhausted gradually. The blockade of PD-L1 signaling resulted in an expansion of tumor specific CD4(+) T cells, which could better control the established metastatic melanoma. Moreover, the tumor-specific memory CD4(+) T cell can prevent mice from tumor metastasis, and the tumor-specific effector CD4(+) T cells can also mitigate the established metastatic tumor. Overall, our findings suggest a novel mechanism of CD4(+) T cells in curtailing tumor metastasis and confirm their therapeutic role in combination with PD-L1 blockade in cancer immunotherapy. Hence, a better understanding of cytotoxic CD4(-) T cell-mediated tumor regression could provide an alternative choice for patients exhibiting suboptimal or no response to CD8(+) T cell-based immunotherapies.

学科与关键词

关键词
tumor specificCD4(+)T cellsCD4(-)T cellsmetastasismelanoma
相关
加载中…
  • The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
    Huang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
  • CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
    Xiao, Minglu; Xie, Luoyingzi; Cao, Guoshuai; Lei, Shun; Wang, Pengcheng; Wei, Zhengping; Luo, Yuan; Fang, Jingyi; Yang, Xingxing; Huang, Qizhao; Xu, Lifan; Guo, Junyi; Wen, Shuqiong; Wang, Zhiming; Wu, Qing; Tang, Jianfang; Wang, Lisha; Chen, Xiangyu; Chen, Cheng; Zhang, Yanyan; Yao, Wei; Ye, Jianqiang*; He, Ran*; Huang, Jun*; Ye, Lilin*Journal for ImmunoTherapy of Cancer, 2022, 10(5): e004022.被引 7
  • Tumor-specific memory CD8+ T cells are strictly resident in draining lymph nodes during tumorigenesis
    Liu, Qiao; Ran, Ling; Yue, Zhengliang; Su, Xingxing; Wang, Lisha; Wen, Shuqiong; Lei, Shun; Yang, Xiaofan; Zhang, Yan; Hu, Jianjun; Tang, Jianfang; Li, Zhirong; Hu, Li; Zhu, Bo; Xu, Lifan*; Ye, Lilin*; Huang, Qizhao*Cellular & Molecular Immunology, 2023, 20(4): 423-426.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-06-16
卷期
第 13 卷
页码
875718
DOI
10.3389/fimmu.2022.875718
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Science and Technology Major Project [2021YFC2300502]; National Science Foundation for Outstanding Young Scholars of China [82122028]; Chongqing Postdoctoral Science Foundation Project [2021YFC2300502]; National Science and Technology Major Project [2021YFC2300502]; National Science Foundation for Outstanding Young Scholars of China [82122028]; Chongqing Postdoctoral Science Foundation Project [2021YFC2300502]; National Natural Science Foundation of China [82122028, cstc2021jcyj-bshX0232]; [319006]; [31900643]

作者

  • L

    Liu, Qiao (通讯) (第一作者)

    third mil med univ

  • W

    Wang, Lisha

    third mil med univ

查看全部 17 位作者收起作者
  • L

    Lin, Huayu

    third mil med univ

  • W

    Wang, Zhiming

    third mil med univ

  • W

    Wu, Jialin

  • G

    Guo, Junyi

    sun yat sen univ

  • W

    Wen, Shuqiong

    sun yat sen univ

  • R

    Ran, Ling

    third mil med univ

  • Y

    Yue, Zhengliang

    third mil med univ

  • S

    Su, Xingxing

    third mil med univ

  • W

    Wu, Qing

    third mil med univ

  • T

    Tang, Jianfang

    third mil med univ

  • L

    Li, Zhirong

    third mil med univ

  • H

    Hu, Li

    third mil med univ

  • X

    Xu, Lifan

    third mil med univ

  • Y

    Ye, Lilin (通讯)

    third mil med univ

  • H

    Huang, Qizhao (通讯)

    third mil med univ · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417